Cullinan Management (NASDAQ:CGEM) reported quarterly losses of $(0.40) per share. This is a 20 percent increase over losses of $(0.50) per share from the same period last year.
Gainers
Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.
Gainers
Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)
Cullinan Management (NASDAQ:CGEM) reported quarterly losses of $(0.36) per share. This is a 18.18 percent increase over losses of $(0.44) per share from the same period last year.